Turning Point Brands: A Modern Oral Pulse Check in Q1 2026

Quarter at a glance

The Louisville, Kentucky–based company posted total consolidated net sales of $124.3 million for the quarter, up 16.8% year over year. A closer look shows a bifurcated product mix: Stoker’s segment sales jumped 48.1%, while Zig-Zag declined 22.4%. The Modern Oral line, a centerpiece of TPB’s strategic pivot, delivered its own dramatic stat: net sales rose 133% to $52.0 million, representing 42% of total net sales.

Gross profit rose 14.6% to $68.3 million, underscoring that top-line momentum did not fully translate into profit expansion. Net income decreased 19.0% to $11.7 million, and adjusted EBITDA slipped 6.5% to $25.9 million. The delta between revenue growth and earnings efficiency is a reminder that scale and mix shifts often come with near-term profitability tradeoffs.

EPS details and what they imply

Diluted earnings per share came in at $0.60, while adjusted diluted EPS stood at $0.76. For context, the year-ago period delivered $0.79 in diluted EPS and $0.91 in adjusted diluted EPS. Those comparisons matter because they illuminate the cost and investment backdrop TPB is navigating as it prudently funds its growth engines in Modern Oral and its legacy brands.

From a “revenue forecast” perspective, the quarter’s performance—driven by a strong Modern Oral showing—appears to validate management’s confidence in the category’s trajectory even as the company absorbs the costs of scaling. The split between reported and adjusted metrics echoes a familiar finance routine: non-GAAP adjustments are meant to help investors see underlying performance without one-time or restructuring noise.

Segment narrative: momentum and headwinds

The Stoker’s brand continued its robust pace with almost half of the overall growth, while Zig-Zag faced a meaningful decline. The contrast underscores TPB’s strategic opportunity to lean into modern formats while managing legacy categories that still contribute but less dynamically to the growth profile.

TPB framed the quarter within a broader transition in nicotine consumption, signaling that the category’s evolution could extend well beyond quarterly results. The company highlighted brand investments, expanded commercial capabilities, and consumer reach as levers to gain share, including through initiatives like a partnership featuring UFC to broaden white pouch momentum.

Guidance and what it portends

TPB reaffirmed and expanded its forward-looking stance: it is raising the FY 2026 Modern Oral sales guidance and introducing FY 2026 EBITDA guidance. This indicates management’s expectation that the Modern Oral franchise will increasingly contribute to the top line while still absorbing initial scaling costs. The emphasis on EBITDA guidance suggests a focus on cash generation and operating discipline even as the company pursues growth investments.

Schedule A for a reconciliation to net income and Schedule B for a reconciliation to diluted EPS are noted in the release. In practice, that means investors can analyze how much of the profitability impact is tied to non-cash items, one-time costs, or other adjustments tied to the growth strategy.

What this could mean for TPB and its peers

From a Matt Levine–style read, the quarter reads as a classic “growth reallocation” moment: a rising Modern Oral franchise pulling on the overall revenue line while the legacy portfolio bears the near-term margin cost. If the trajectory in Modern Oral continues to outpace the rest of the portfolio, TPB could see a broader re-rating on the back of improved revenue visibility and a clearer path to mid-single-digit to low-double-digit top-line growth.

For sector peers, the message is twofold. First, there’s evidence that category shifts toward modern formats can unlock revenue growth even when traditional segments falter. Second, investors will watch for how well management translates top-line momentum into sustainable earnings power, which hinges on cost discipline, go-to-market execution, and channel expansion.

Risks and considerations

The margin compression that often accompanies rapid product diversification deserves caution. While Modern Oral sales accelerated, net income declined year over year, suggesting higher investment spend and competitive dynamics in a transitioning market. Regulatory considerations, consumer preferences, and competitive responses in the nicotine and consumables space remain important risk factors for TPB and its peers.

Bottom line

TPB’s Q1 2026 results illuminate a company actively shifting its mix toward a higher-growth, higher-visibility Modern Oral franchise while juggling the costs of scaling and maintaining profitability in legacy segments. The raised guidance for Modern Oral sales and the new EBITDA target signal a commitment to translating top-line momentum into rising cash flow over the course of 2026. For investors tracking EPS, revenue forecasts, and the earnings surprises that often accompany transformative portfolios, TPB offers a case study in how to balance ambition with discipline as the nicotine category evolves.